Company profile: Revagenix
1.1 - Company Overview
Company description
- Provider of infectious disease therapeutics, including a late-preclinical broad-spectrum antimicrobial for cUTI, HABP, VABP, neonatal sepsis and BSI; a novel agent to reduce care burden in chronic pulmonary infections; a treatment with a novel mechanism for challenging Gram-negative infections; and an on-hold pipeline of Gram-negative antibacterials that can be activated within 12-18 months.
Products and services
- Lead Program: Broad-spectrum antimicrobial agent in late preclinical stage, engineered to treat cUTI, HABP, VABP, neonatal sepsis, and bloodstream infections across diverse infection types
- Third Program: Novel mechanism-of-action treatment developed to combat challenging Gram-negative infections, engineered to address hard-to-treat Gram-negative pathogens
- Second Program: Novel agent aimed at reducing the burden of care in treating chronic pulmonary infections, produced to ease treatment demands during long-term respiratory infection management
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Revagenix
Tevogen Bio
HQ: United States
Website
- Description: Provider of immunotherapy solutions focused on T cell therapies for infectious diseases, cancers, and neurological disorders. Offerings include the ExacTcell platform utilizing CD8+ cytotoxic T lymphocytes; TVGN 489, an investigational therapy for high-risk COVID-19 and potential Long COVID; Tevogen.AI to accelerate development and target detection; and the TCTL trial in adults with newly diagnosed COVID-19.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tevogen Bio company profile →
DNAe
HQ: United Kingdom
Website
- Description: Provider of rapid near-patient molecular diagnostics, offering the LiDia-SEQ platform for direct-from-specimen DNA sequencing on a microchip; BSI/AMR test detecting bloodstream infections and antimicrobial resistance from whole blood; a sample preparation system extracting pathogens via immunomagnetic beads; semiconductor sequencing technology; and an oncology program for tumor DNA monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DNAe company profile →
NanoCures
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology and infectious disease immunity platforms, including: Cures Platform targeting specific genomic and molecular pathways to yield multiple therapeutics; Data/AI Platform using biometric, genomic, molecular, and environmental data with AI/ML to detect diseases early and guide new cure development; and Developer Platform offering resources, data, and tools to lower barriers and encourage innovation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoCures company profile →
Ansun BioPharma
HQ: United States
Website
- Description: Provider of host-directed antivirals and solid tumor therapies. Offers DAS181, a recombinant sialidase that removes sialic acids from respiratory epithelial cells to block viral entry and treat parainfluenza and influenza. Develops multi-modality platforms targeting tumor and immune cells to prevent immune escape and restore tumor surveillance, including oncolytic viruses, bispecific antibodies, and CAR-NK/γδ T cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ansun BioPharma company profile →
Abac Therapeutics
HQ: Spain
Website
- Description: Provider of precision antimicrobial drug discovery and development, creating first-in-class, pathogen-specific antibiotics for MDR Gram-negative infections. Offers the PasNas scalable, multiplexed platform to identify high-quality leads across compounds and bacterial species, and advances agents with suitable pharmacokinetics/toxicology, leveraging public-private collaborations to combat antimicrobial resistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abac Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Revagenix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Revagenix
2.2 - Growth funds investing in similar companies to Revagenix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Revagenix
4.2 - Public trading comparable groups for Revagenix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →